
Sight Sciences (SGHT) Stock Forecast & Price Target
Sight Sciences (SGHT) Analyst Ratings
Bulls say
Sight Sciences Inc's positive outlook is supported by potential drivers for revenue growth, including faster-than-anticipated market share gains in the minimally invasive glaucoma surgery (MIGS) segment and accelerated adoption of its TearCare system. The company is positioned to sustain growth in its Surgical Glaucoma segment, which aligns with the overall MIGS market trends. Additionally, revised earnings per share (EPS) projections for 2025 and 2026 reflect a decrease in losses, indicating an improving financial trajectory as the company aims towards profitability.
Bears say
Sight Sciences Inc. has reiterated its revenue guidance for 2025 in the range of $72-76 million, while simultaneously forecasting a mid-single-digit percentage decline in Surgical Glaucoma revenue for the third quarter of 2025, indicating challenges in its primary revenue-generating segment. Additionally, the company faces significant risks including heightened competition in the minimally invasive glaucoma surgical (MIGS) market, slow advancement towards securing insurance coverage for its TearCare product, and persistent quarterly cash burn issues. Although management has adjusted its operating expense guidance downward, anticipating annualized savings of $12 million, the overall financial outlook remains pressured by these obstacles and declining revenue expectations.
This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares